Skip to main content
MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
2.360
+0.130 (5.83%)
At close: Mar 9, 2026, 4:00 PM EDT
2.380
+0.020 (0.85%)
After-hours: Mar 9, 2026, 6:42 PM EDT

MacroGenics Revenue

MacroGenics had revenue of $72.84M in the quarter ending September 30, 2025, a decrease of -34.21%. This brings the company's revenue in the last twelve months to $127.63M, down -9.70% year-over-year. In the year 2024, MacroGenics had annual revenue of $149.96M with 155.26% growth.

Revenue (ttm)
$127.63M
Revenue Growth
-9.70%
P/S Ratio
1.17
Revenue / Employee
$374,270
Employees
341
Market Cap
149.29M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024149.96M91.21M155.26%
Dec 31, 202358.75M-93.19M-61.33%
Dec 31, 2022151.94M74.49M96.19%
Dec 31, 202177.45M-27.44M-26.16%
Dec 31, 2020104.88M40.70M63.40%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Karyopharm Therapeutics 146.07M
Sangamo Therapeutics 32.88M
Zentalis Pharmaceuticals 26.87M
Innate Pharma 14.84M
Fate Therapeutics 6.65M
Connect Biopharma Holdings 762.00K
Artiva Biotherapeutics 251.00K
Adagene 103.20K
Revenue Rankings

MGNX News

More News